Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Fluoxetine: Difference between revisions

From Pharmacopedia
[checked revision][checked revision]
Fluoxetine: history-first intro rewrite and new History section (discovery at Eli Lilly 1972, Prozac launch, mechanism note)
No edit summary
Line 21: Line 21:
| legal            = Rx-only in US
| legal            = Rx-only in US
| mechanism        = TrkB/BDNF<ref name="trkb">S1</ref> <vote slug="ssri-claim">Fluoxetine is a selective serotonin reuptake inhibitor.</vote>
| mechanism        = TrkB/BDNF<ref name="trkb">S1</ref> <vote slug="ssri-claim">Fluoxetine is a selective serotonin reuptake inhibitor.</vote>
| intro            = Fluoxetine, marketed as Prozac, was the first selective serotonin reuptake inhibitor brought to market and the medicine that opened the SSRI era. It was discovered at Eli Lilly's laboratories in Indianapolis on 24 July 1972 by a team that included the chemists Bryan Molloy and Klaus Schmiegel and the pharmacologist David Wong,<ref name="wong1974">Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sciences. 1974;15(3):471-479. PMID: 4549929.</ref> approved by the FDA in December 1987, and launched in the United States as Prozac in January 1988. It is notable for the extremely long half-life of its active metabolite norfluoxetine, which gives the medicine an unusually mild discontinuation profile and makes it useful as a bridge in tapering patients off shorter-acting serotonergic medicines.
| intro            = Fluoxetine, marketed as Prozac, was the first selective serotonin reuptake inhibitor ([[Category:Selective_Serotonin_Reuptake_Inhibitors_(SSRIs)|SSRIs]]) brought to market and the medicine that opened the SSRI era. It was discovered at Eli Lilly's laboratories in Indianapolis on 24 July 1972 by a team that included the chemists Bryan Molloy and Klaus Schmiegel and the pharmacologist David Wong,<ref name="wong1974">Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sciences. 1974;15(3):471-479. PMID: 4549929.</ref> approved by the FDA in December 1987, and launched in the United States as Prozac in January 1988. It is notable for the extremely long half-life of its active metabolite norfluoxetine, which gives the medicine an unusually mild discontinuation profile and makes it useful as a bridge in tapering patients off shorter-acting serotonergic medicines.
| history          = The compound that became fluoxetine emerged from an Eli Lilly program that began in the late 1960s under Molloy and Schmiegel, who synthesized a series of aryloxyphenylpropylamines starting from the antihistamine diphenhydramine as a structural lead. Wong, who had followed the European literature implicating serotonin in mood regulation, proposed screening the new compounds specifically for serotonin uptake inhibition. On 24 July 1972 the team identified the compound then designated Lilly 110140 as a potent and selective inhibitor of serotonin uptake in rat brain synaptosomes. The finding was published in 1974 as the first description of what is now known as a selective serotonin reuptake inhibitor.<ref name="wong1974"/>
| history          = The compound that became fluoxetine emerged from an Eli Lilly program that began in the late 1960s under Molloy and Schmiegel, who synthesized a series of aryloxyphenylpropylamines starting from the antihistamine diphenhydramine as a structural lead. Wong, who had followed the European literature implicating serotonin in mood regulation, proposed screening the new compounds specifically for serotonin uptake inhibition. On 24 July 1972 the team identified the compound then designated Lilly 110140 as a potent and selective inhibitor of serotonin uptake in rat brain synaptosomes. The finding was published in 1974 as the first description of what is now known as a selective serotonin reuptake inhibitor.<ref name="wong1974"/>